ContextLogic Stock Is Tumbling After Hours: What’s Happening?

ContextLogic Inc (NASDAQ: WISH) shares are crumbling after the close Thursday following the company's quarterly results.

ContextLogic Inc (NASDAQ:WISH) shares are crumbling after the close Thursday following the company’s quarterly results.

  • Q2 Revenue: $78 million missed estimates of $94.25 million 
  • Q2 EPS: loss of $3.38 beat estimates for a loss of $3.74

Revenues were down 42% year-over-year. Core marketplace volumes were down 56%, product boost revenues were down 45%, and logistics revenues were down 30%. 

“Our second quarter results reflect a continuingly challenging operating environment. While our adjusted EBITDA results were in-line with expectations, we experienced macro and competitive pressure on our top-line performance,” said Joe Yan, CEO of Wish.

“Looking ahead to the remainder of the year, we recognize that macroeconomic uncertainties and competitive pressures will likely persist.”

ContextLogic said it’s taking aggressive actions to lower its cost structure and improve operational efficiencies significantly.

Third-quarter revenue is expected to be between $55 million and $65 million. The company anticipates an adjusted EBITDA loss of $55 million to $65 million.

WISH Price Action: Wish shares were down 11.10% after hours at $7.45 at the time of publication, according to Benzinga Pro.

Photo: StockSnap from Pixabay.

Total
0
Shares
Related Posts
Read More

CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment

There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB). But, treatments to help alleviate and control the symptoms do exist. The growing body of research suggests cannabinoid-based medicines help ease pain and pruritus in those with a disorder while improving wound healing.The latest scientifically prove healing power of cannabis was Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products.

AVCNF